Nicox Sa · EURONEXT:ALCOX
Nicox Sa — Investor Presentation (October 2024)
30 slides from Nicox Sa's investor presentation, Oct 17, 2024
Slide 1: Nicox Corporate Presentation
Nicox Corporate Presentation An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health October 17, 2024
Slide 2: Forward-Looking statements
Forward-Looking statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to, an
Slide 3: Progress in achieving value inflection points expected for 2024-2025
Progress in achieving value inflection points expected for 2024-2025 Appointment of Gavin Spencer as Chief Executive Officer Nicox Board entirely renewed with appointment of Damian Marron as Chair and 3 new Board members Restructuring of debt agreements with BlackRock Streamlining costs to concentra
Slide 4: Consistently delivering innovations in ophthalmology
Consistently delivering innovations in ophthalmology ... stage Phase 3 development al partnerships with r 1 ophthalmology players ep ophthalmology experience >» A potentially differentiated profile targeting ~$6bn worldwide glaucoma market Positive results from the first Phase 3 trial’, Mont Blanc,
Slide 5: Upcoming milestones
Upcoming milestones Several positive milestones in 2024 and 2025 NCX 470 ** Denali results — Q3 2025 “ Whistler results — Q1 2025 “ Estimated potential worldwide sales over $300 million! ZERVIATE “ Upcoming Launch in China Corporate “ Ongoing partnership discussions “+ Potential NCX 1728 license opt
Slide 6: Revenue sold to Soleus Capital; approved in China
Revenue sold to Soleus Capital in October 2024 Approved in China in September 2024
Slide 7: Glaucoma: a worldwide ophthalmic condition with unmet medical needs
Glaucoma: a worldwide ophthalmic condition with unmet medical needs Elevated IOP* contributes to irreversible optic nerve damage, Leading to progressive vision Loss normal aqueous humor outflow \ vitreous: anterior chamber ens —+ optic nerve head posterior chamber healthy eye chamber damage to the o
Slide 8: Unmet medical needs for glaucoma treatment
Unmet medical needs for glaucoma treatment Y¥ 40% of patients do not achieve their target IOP on existing monotherapies' V Tolerability issues with some medications lead to discontinuations, Despite having well established first-line therapies, including the standard-of-care, latanoprost, patients d
Slide 9: NCX 470 lowers IOP through a validated dual mechanism pathway
NCX 470 lowers IOP through a validated’ dual mechanism pathway Clinically validated with the first NO-donating PGA, VYZULTA® Two pathways for Primary or conventional aqueous humor outflow outflow normally accounts for ~60% to 80% of outflow anterior laaaes * | °) chamber ~ NCX 470 posterior chamber
Slide 10: Positive NCX 470 Mont Blanc topline results
Positive NCX 470 Mont Blanc topline results’? Phase 3 clinical program intended to support U.S. & China NDA submissions Designed to demonstrate safety and efficacy of NCX 470 0.1% vs. Latanoprost 0.005%, studies will evaluate reduction of IOP from time-matched baseline at pre-established time points
Slide 11: Mont Blanc trial schematic
1. This schematic reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial
Slide 12: EMGT study: each mmHg of decreased IOP lowers risk
As published in the landmark EMGT study “…each mmHg of decreased IOP was related to an approximately 10% lowering [of risk of vision loss progression]”1 1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design
Slide 13: NCX 470 0.1% vs Latanoprost 0.005% results
NCX 470 0.1%: N = 328 Latanoprost 0.005%: N = 333 • Denotes statistically significant differences vs latanoprost (p<0.049) • Fechtner et al., AJO, published, 2024 - https://doi.org/10.1016/j.ajo.2024.03.002
Slide 14: IOP reduction versus latanoprost
• * * * * • • * Denotes statistically significant differences vs latanoprost (p<0.049)
Slide 15: NCX 470 was well tolerated
• • • • ≤ • • NCX 470 was well • • • 1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial.
Slide 16: NCX 470 presentations at key ophthalmology conferences
NCX 470 - Presentations at key ophthalmology conferences OM ERAN + Poster 1: Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular SOCIETY Pressures + Poster 2: Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated V
Slide 17: Authors' conclusion on NCX 470 0.1%
Authors’ conclusion: The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important
Slide 18: NCX 1728 initial exploratory studies
Initial exploratory studies generated encouraging results Next Steps 1. Bastia et al., J Ocul Pharmacol Ther. 2022, 38: 496-504; 2. Sgambellone et al., Transl Vis Sci Technol. 2023, 1;12(9):22.
Slide 19: U.S. glaucoma clinical advisory board with leading experts
U.S. glaucoma clinical advisory board with leading experts DR. ROBERT D. FECHTNER, MD, CHAIRMAN Professor and Chair of the Department of Ophthalmology at SUNY Upstate Medical University, Syracuse, NY DR. SANJAY G. ASRANI, MD Professor of Ophthalmology at Duke University in Durham, North Carolina, an
Slide 20: Value proposition of NCX 470
Value proposition of NCX 470 < fe} S 2 Novel molecule with competitive positive impact on lowering intraocular pressure (IOP), the leading cause of glaucoma Positive pivotal Phase 3 topline results from the Mont Blanc trial!23 First non-combination product to demonstrate statistical non-inferiority
Slide 21: NCX 470 patent protection and sales potential
*Subject to securing a U.S. commercial partner • Composition of matter patent to 2029 expected to be extended to 2034 in the United States and formulation patent to 2039. Additional marketing exclusivity may be available based on the status as a New Chemical Entity • Peak annual net sales potential
Slide 22: Ocumension Therapeutics partnership
Portfolio of 25 Listed on the 444 employees, Based in China products with Hong Kong stock including 232 in Created in 2018 10 commercialised exchange since commercial Dedicated to $34 million revenue 2020 ophthalmology in 2023 (+55%) $600 million market cap • • •
Slide 23: Kowa partnership
Founded in Japan in 1894 ~8000 employees The pharmaceutical Team of medical Active worldwide with an annual sector is an representatives in in multiple group revenue of important one with Japan and a domains including $4.9 billion an international franchise in life sciences presence glaucoma • • •
Slide 24: Future commercialization of NCX 470
Future commercialization of NCX 470 To secure the Long-term future of the Company * The Company is considering a number of options to ensure the commercialization of NCX 470 and concretize the future strategy: * New license agreements * — Joint venture structures with companies having complementary
Slide 25: Existing commercial products: VYZULTA and ZERVIATE
.) Existing commercial products VYZULTA BAUSCH +LOMB v 5% to 9% royalties on annual net sales 0] OcuMension v Potential for up to $17.2 million in sales milestones by Ocumension BEES v Will be manufactured by Ocumension in their state-of-the art Chinese Approved in China in 2024 factory and commerci
Slide 26: NCX 1728 mechanism of action
• • • • MOA = Mechanism of Action GTP = guanosine triphosphate sGC = soluble guanylate cyclase cGMP = cyclic guanosine monophosphate, PKG – protein kinase G ER = endoplasmic reticulum Ca++ = Calcium
Slide 27: A refocused global leadership team
A refocused global leadership team Na Gavin Spencer Sandrine Gestin Doug Hubatsch Emmet Purtill Chief Executive Officer VP, Finance and HR EvP, Chief Scientific Officer VP Business Development Ub NovaRTIS tb NOVARTIS Qa Alcon COVANCE INTERNATIONAL Sonia Benhamida Observer BlackRock Damian Marron Chr
Slide 28: Financial highlights
Financial highlights Cash balance expected to support current operations through to Q3 2025 Financial Position and Ownership of the Nicox Group’ €19.7 million including estimated net proceeds? from October Cash, Cash Equivalents as at 30 September 2024 financing Long term debt as at 30 September 202
Slide 29: Investment highlights
Investment highlights proven track record in clinical development and business develo * Two product approvals in the U.S., one in China * Business development deals in the U.S., Japan, China, and globally with Tier 1 companies v NCX 470, a derisked, late-stage development program * Positive Mont Bla
Slide 30: Nicox S.A.
30 Nicox S.A. Sundesk Sophia Antipolis Emerald Square Batiment C rue Evariste Galois, 06410 Biot, France T: +33 (0)4 97 24 53 00 nicox visible science COMMUN ications@ nicox.com WWww.nicox.com, (@